

Colorado HB 19-1131 Product Disclosure Details

The following product pricing and competitor information is being disclosed as prescribed by Colorado HB 19-1131. The notice below provides the Wholesale Acquisition Cost (“WAC”) and the names of generic prescription drugs available in the same therapeutic class as Kyowa Kirin’s products based on the products’ labeled indications.

The prices listed below are WAC prices as published by AnalySource. WAC prices are representative of the price paid by wholesalers but the actual price paid by consumers may differ significantly from the WAC prices listed below. Further, the WAC prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Marketed Product Name	Manufacturer	NDC	Package Size	Package WAC Price
CRYSVITA® (burosumab-twza) injection, for subcutaneous use 10 MG/ML	Kyowa Kirin, Inc.	42747-0102-01	1 ML, Unit-Dose, Vial	\$4,451.45
CRYSVITA® (burosumab-twza) injection, for subcutaneous use 20 MG/ML	Kyowa Kirin, Inc.	42747-0203-01	1 ML, Unit-Dose, Vial	\$8,902.91
CRYSVITA® (burosumab-twza) injection, for subcutaneous use 30 MG/ML	Kyowa Kirin, Inc.	42747-0304-01	1 ML, Unit-Dose, Vial	\$13,354.36

Generics in the same therapeutic class*

None

Colorado law requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed drug. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.”

As of the date of this form there is no generic version of burosumab-twza available in the United States.

There are currently no generic prescription drugs in the same “therapeutic class” as CRYSVITA®.

Please refer to each product’s FDA-approved label and indication for further information.

Colorado HB 19-1131 Product Disclosure Details

The following product pricing and competitor information is being disclosed as prescribed by Colorado HB 19-1131. The notice below provides the Wholesale Acquisition Cost (“WAC”) and the names of generic prescription drugs available in the same therapeutic class as Kyowa Kirin’s products based on the products’ labeled indications.

The prices listed below are WAC prices as published by AnalySource. WAC prices are representative of the price paid by wholesalers but the actual price paid by consumers may differ significantly from the WAC prices listed below. Further, the WAC prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Marketed Product Name	Manufacturer	NDC	Package Size	Package WAC Price
NOURIANZ™	Kyowa Kirin, Inc.	42747-0602-90	90	\$ 5,678.15
NOURIANZ™	Kyowa Kirin, Inc.	42747-0604-90	90	\$ 5,678.15

Generics in the same therapeutic class*

None

Colorado law requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed drug. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.”

As of the date of this form there is no generic version of istradefylline available in the United States. There are currently no generic prescription drugs in the same “therapeutic class” as NOURIANZ™.

Please refer to each product’s FDA-approved label and indication for further information.

*Generic Competitor Data Source: AnalySource
WAC Prices Last Updated On: January 5, 2024

Colorado HB 19-1131 Product Disclosure Details

The following product pricing and competitor information is being disclosed as prescribed by Colorado HB 19-1131. The notice below provides the Wholesale Acquisition Cost (“WAC”) and the names of generic prescription drugs available in the same therapeutic class as Kyowa Kirin’s products based on the products’ labeled indications.

The prices listed below are WAC prices as published by AnalySource. WAC prices are representative of the price paid by wholesalers but the actual price paid by consumers may differ significantly from the WAC prices listed below. Further, the WAC prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Marketed Product Name	Manufacturer	NDC	Package Size	Package WAC Price
POTELIGEO® (mogamulizumab-kpkc) injection	Kyowa Kirin, Inc.	42747-0761-01	20 mg/5 mL single-dose vial	\$4,596.56

Generics in the same therapeutic class*

None

*Colorado law requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed drug. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.”

*As of the date of this form there is no generic version of mogamulizumab available in the United States. Please refer to each product’s FDA-approved label and indication for further information. There are currently no generic prescription drugs in the same “therapeutic class” as Poteligeo.